To access this element change to forms mode OFF
Grant Award View - GA52662
Targeting Polo-like kinase 1 as a novel therapeutic opportunity for...
GA ID:
GA52662
Agency:
Cancer Australia
Approval Date:
28-May-2019
Publish Date:
3-Jul-2019
Category:
Cancer
Grant Term:
28-May-2019 to 27-May-2022
Value (AUD):
$278,281.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 18/19 Improved cancer control
Grant Program:
2018 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
Targeting Polo-like kinase 1 as a novel therapeutic opportunity for Diffuse Intrinsic Pontine Gliomas
Purpose:
DIPG is the most aggressive cancer to affect children, with no known curative therapies. The Investigators have found that a new class of drugs called PLK1 inhibitors are highly potent against the first DIPG cells ever grown in the laboratory. The Investigators aim to use this discovery to develop the optimal combination therapy, in order to be able to rapidly translate these findings to the clinic, to directly benefit children with DIPG.
GO ID:
GO Title:
2018 PdCCRS Project Grants for funding commencing 2019
Internal Reference ID:
2018 PdCCRS
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Kensington
Town/City:
Sydney
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
National
Postcode:
Multiple
Country:
AUSTRALIA